Literature DB >> 15534185

The natural history of Alzheimer disease: a longitudinal presymptomatic and symptomatic study of a familial cohort.

Alison K Godbolt1, Lisa Cipolotti, Hilary Watt, Nick C Fox, John C Janssen, Martin N Rossor.   

Abstract

BACKGROUND: Knowledge of the evolution of cognitive deficits in Alzheimer disease is important for our understanding of disease progression. Previous reports, however, have either lacked detail or have not covered the presymptomatic stages.
OBJECTIVE: To delineate the onset and progression of clinical and neuropsychological abnormalities in familial Alzheimer disease.
METHODS: Nineteen subjects with familial Alzheimer disease underwent serial clinical and neuropsychological assessments. Eight of these had undergone presymptomatic assessments. The follow-up period was 1 to 10 years (mean, 5 years). The relative timing of the occurrence of 3 markers of disease onset and progression (onset of symptoms, Mini-Mental State Examination score < or = 24, and impaired scores on a range of neuropsychological tests) were compared using the binomial exact test.
RESULTS: Neurological abnormalities were not prominent, although myoclonus appeared early in some. Mini-Mental State Examination score was not sensitive to early disease. Memory and general intelligence deficits appeared at an earlier stage, in some patients when presymptomatic. Perceptual, naming, and especially spelling skills were preserved to a late stage.
CONCLUSION: Familial Alzheimer disease may have a long prodromal phase of several years with subtle deficits initially of general intelligence and memory, while spelling, naming, and perception are relatively preserved until a late stage.

Entities:  

Mesh:

Year:  2004        PMID: 15534185     DOI: 10.1001/archneur.61.11.1743

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  21 in total

1.  Lack of association between 11C-PiB and longitudinal brain atrophy in non-demented older individuals.

Authors:  Ira Driscoll; Yun Zhou; Yang An; Jitka Sojkova; Christos Davatzikos; Michael A Kraut; Weiguo Ye; Luigi Ferrucci; Chester A Mathis; William E Klunk; Dean F Wong; Susan M Resnick
Journal:  Neurobiol Aging       Date:  2010-02-21       Impact factor: 4.673

Review 2.  The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics.

Authors:  Eric Karran; Marc Mercken; Bart De Strooper
Journal:  Nat Rev Drug Discov       Date:  2011-08-19       Impact factor: 84.694

Review 3.  Asymptomatic Alzheimer's disease: a prodrome or a state of resilience?

Authors:  I Driscoll; J Troncoso
Journal:  Curr Alzheimer Res       Date:  2011-06       Impact factor: 3.498

4.  Rare causes of early-onset dystonia-parkinsonism with cognitive impairment: a de novo PSEN-1 mutation.

Authors:  Miryam Carecchio; Marina Picillo; Lorella Valletta; Antonio E Elia; Tobias B Haack; Autilia Cozzolino; Annalisa Vitale; Barbara Garavaglia; Arcangela Iuso; Caterina F Bagella; Sabina Pappatà; Paolo Barone; Holger Prokisch; Luigi Romito; Valeria Tiranti
Journal:  Neurogenetics       Date:  2017-06-29       Impact factor: 2.660

Review 5.  Correlating familial Alzheimer's disease gene mutations with clinical phenotype.

Authors:  Natalie S Ryan; Martin N Rossor
Journal:  Biomark Med       Date:  2010-02       Impact factor: 2.851

6.  Psychosis in "Cognitively Asymptomatic" Elderly Subjects is Associated With Neuritic Plaque Load, Not Neurofibrillary Tangles.

Authors:  Julia Kim; Tom A Schweizer; Corinne E Fischer; David G Munoz
Journal:  Alzheimer Dis Assoc Disord       Date:  2018 Jul-Sep       Impact factor: 2.703

7.  Familial dementia with frontotemporal features associated with M146V presenilin-1 mutation.

Authors:  Miguel A Riudavets; Leonardo Bartoloni; Juan C Troncoso; Olga Pletnikova; Peter St George-Hyslop; Marcelo Schultz; Gustavo Sevlever; Ricardo F Allegri
Journal:  Brain Pathol       Date:  2013-04-25       Impact factor: 6.508

8.  Plasma growth hormones, P300 event-related potential and test of variables of attention (TOVA) are important neuroendocrinological predictors of early cognitive decline in a clinical setting: evidence supported by structural equation modeling (SEM) parameter estimates.

Authors:  Eric R Braverman; Thomas J H Chen; Thomas J Prihoda; William Sonntag; Brian Meshkin; B William Downs; Julie F Mengucci; Seth H Blum; Alison Notaro; Vanessa Arcuri; Michael Varshavskiy; Kenneth Blum
Journal:  Age (Dordr)       Date:  2007-05-12

Review 9.  Genetic aspects of Alzheimer disease.

Authors:  Thomas D Bird
Journal:  Genet Med       Date:  2008-04       Impact factor: 8.822

10.  Genetic influences on atrophy patterns in familial Alzheimer's disease: a comparison of APP and PSEN1 mutations.

Authors:  Rachael I Scahill; Gerard R Ridgway; Jonathan W Bartlett; Josephine Barnes; Natalie S Ryan; Simon Mead; Jonathan Beck; Matthew J Clarkson; Sebastian J Crutch; Jonathan M Schott; Sebastien Ourselin; Jason D Warren; John Hardy; Martin N Rossor; Nick C Fox
Journal:  J Alzheimers Dis       Date:  2013       Impact factor: 4.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.